Company Profile

Achillion Pharmaceuticals Inc
Profile last edited on: 11/1/22      CAGE: 5DEY9      UEI: GM9GNHYTG251

Business Identifier: Anti-infective agents: HIV, hepatitis and resistant bacterial infections.
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 George Street
New Haven, CT 06511
   (203) 624-7000
Location: Single
Congr. District: 03
County: New Haven

Public Profile

In October 2019 it was announced that Achillion Pharmaceticals (NASDAQ:ACHN) had been acquired by Alexion Pharmaceuticals - a biopharmaceutical company engaged in biologic therapeutics. Organzied primarily around advancing its orally administered factor D inhibitors into late-stage development and commercialization, Achillion Pharmaceuticals, Inc., had functioned as an biopharmaceutical company, engaged in the discovery, development, and commercialization of treatments for infectious diseases. It was reported that Achillion would continue operations as a subsiduary of the acquriing firm. Focused on the development of antivirals for the treatment of HIV infection and chronic hepatitis C; and antibacterials for the treatment of serious hospital-based bacterial infections, Acillion's lead drug candidate is elvucitabine, an antiviral in phase II clinical trials for the treatment of HIV infection. Also under development is ACH-702, a preclinical candidate for the treatment of serious hospital-based bacterial infection; and NS4A Antagonists, a preclinical-stage program for chronic hepatitis C. The company had previsuly had been in research collaborations with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic hepatitis C.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $300,000
Project Title: Novel Antibacterial Agents That Target DNAReplication in Mycobacterium Tuberculo
2006 2 NIH $597,665
Project Title: Capsid assembly inhibitors for the treatment of AIDS

Key People / Management

  Milind Deshpande -- Chief Exec. Officer and President

  Michael D Kishbauch -- President & Chief Executive Officer

  Atul Agarwal

  David Apelian -- Chief Medical Officer and Exec. Vp

  Joel C Barrish -- Chief Scientific Officer and Exec. Vp

  Jerome Birnbaum -- Co-Founder and Senior Scientific Advisor

  Mary Kay Fenton -- Vice President and Chief Financial Officer

  John C Pottage -- Senior Vice President and Chief Medical Office

  Michael J Pucci

  Gautam Shah -- Senior Vice President and Chief Compliance Officer

  Joe Truitt -- Senior Vice President of Business Development and Chief Commercial Officer